Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Chem Biol. 2008 Aug;12(4):434-40. doi: 10.1016/j.cbpa.2008.06.033. Epub 2008 Jul 24.

Advances in and applications of proteasome inhibitors.

Author information

  • 1Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California at San Diego, La Jolla, CA 92093, USA. bsmoore@ucsd.edu

Abstract

With the recent US Food and Drug Administration approval of bortezomib (Velcade) for the treatment of relapsed multiple myeloma, the proteasome has emerged as a new therapeutic target with diverse pathology. Drug discovery programs in academia and the pharmaceutical industry have developed a range of low nanomolar synthetic and natural inhibitors of the 20S proteasome core particle that have entered human clinical trials as significant anti-cancer and anti-inflammatory leads. Moreover, proteasome inhibitors continue to serve as valuable research tools in cellular biology through the elucidation of important biological processes associated with the ubiquitin-proteasome pathway of protein degradation. This review will highlight recent advances in the development and application of proteasome inhibitors.

PMID:
18656549
[PubMed - indexed for MEDLINE]
PMCID:
PMC2560982
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk